- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06867120
Bowel Sound in Predicting the Severity of Acute Pancreatitis: Protocol of a Prospective, Multi-center Study
Introduction: Acute pancreatitis (AP) is a common condition, with 20% of cases progressing to severe acute pancreatitis (SAP), which is associated with a poor prognosis. Early identification of patients likely to progress to SAP is crucial for timely intervention. This study aims to use bowel sound monitoring to predict early progression to SAP in AP patients.
Methods and analysis: This study is a prospective, multi-center prognostic study . Investigators will consecutively recruit newly diagnosed acute pancreatitis (AP) patients at emergency departments across three centers from December 2023. Upon enrollment, each patient will undergo continuous bowel sound monitoring for at least 48 hours using standardized equipment and procedures. The primary outcome is the occurrence of SAP during hospitalization. Collected bowel sound data will be analyzed by an unsupervised automated algorithm to estimate a bowel sound activity index, which serves as the main diagnostic indicator for SAP. This process will be fully blinded to patients' SAP status. Investigators will calculate the ROC curve and area under the curve (AUC) for the bowel sound activity index's ability to diagnose SAP. Additionally, this study will perform exploratory analyses on differences in gut microbiota and serum intestinal permeability markers (diamine oxidase, D-lactic acid, and bacterial endotoxin) between patients with and without SAP. Investigators will also assess whether bowel sound monitoring can reflect these inter-group differences.
Strengths and limitations of the study:
- Our research aims to monitor bowel sounds in real-time and dynamically, providing an objective tool for monitoring intestinal activity in AP patients.
- Our research might offer an objective tool to evaluate bowel sounds, aiding in assessing AP patients' intestinal function and complementing existing score systems like the modified Marshall score.
- By detecting bowel sounds in the early stage of AP, investigators could better monitor intestinal function, which might aid in predicting the prognosis of AP patients.
- Our monitoring system's main limitation is its difficulty in pinpointing bowel sound changes in specific intestinal segments due to its detection across the entire abdomen.
Study Overview
Status
Conditions
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Contact
- Name: Ziying Han, Doctor of Medicine
- Phone Number: +86 15811301605
- Email: hanziying@pumch.cn
Study Locations
-
-
Beijing Municipality
-
Beijing, Beijing Municipality, China, 100000
- Recruiting
- Peking Union Medical College Hospital
-
Contact:
- Ziying Han, Doctor of Medicine
- Phone Number: +86 15811301605
- Email: hanziying@pumch.cn
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion criteria:
- Aged between 18 and 85 years old.
- Meet the diagnostic criteria for AP, at least two of the following three: (a) characteristic abdominal pain; (b) serum amylase and lipase levels are greater than three times the upper limit of normal; (c) abdominal images with typical manifestations of AP.
- AP patients within 48 hours of onset.
- The patient or family members understand the study protocol and sign the informed consent form.
Exclusion criteria:
The patients who fulfill any of the following criteria will be excluded:
- Patients with serious conditions requiring surgery and abdominal lavage.
- Pregnant women.
- The patients with muscle and nerve disorders, chronic pancreatitis, inflammatory bowel disease, cancer, and irritable bowel syndrome.
- The patients with severe digestive, respiratory, cardiovascular, hematological, endocrine, psychiatric, and infectious diseases.
- The patients have a history of abdominal surgery (except appendectomy or cholecystectomy).
- Allergic to silicone, polycarbonate materials or medical plaster. The intake of antibiotic, probiotics, and Chinese herbal medicine will be recorded before the collection of the swabs and will not be considered as exclusion criteria.
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
|---|
|
Observational Cohort
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of participants with severe acute pancreatitis (SAP) during hospitalization within 7 days after enrollment.
Time Frame: Within 7 days after enrollment.
|
SAP was defined as AP patients with persistent organ failure according to the revised Atlanta classification.
|
Within 7 days after enrollment.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of participants with in-hospital mortality.
Time Frame: Within 30 days after enrollment.
|
Number of participants who died during hospitalization.
|
Within 30 days after enrollment.
|
|
Number of participants with 30-day mortality.
Time Frame: Within 30 days after enrollment.
|
Number of participants who died within 30 days after enrollment.
|
Within 30 days after enrollment.
|
|
Length of hospital stay.
Time Frame: Within 30 days after enrollment.
|
The number of days participants stayed in the hospital.
|
Within 30 days after enrollment.
|
|
Number of participants with organ failure.
Time Frame: Within 30 days after enrollment.
|
Number of participants who developed organ failure.
|
Within 30 days after enrollment.
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- I-25PJ1400
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Severe Acute Pancreatitis
-
Changhai HospitalRecruitingAcute Pancreatitis | Severe Acute PancreatitisChina
-
Ruijin HospitalShanghai Municipal Science and Technology CommissionActive, not recruitingSevere Acute PancreatitisChina
-
Fundació Institut de Recerca de l'Hospital de la...UnknownSevere Acute PancreatitisSpain
-
University Hospital, GenevaCompletedSevere Acute PancreatitisSwitzerland
-
Fujian Shengdi Pharmaceutical Co., Ltd.RecruitingSevere Hypertriglyceridemia With a High Risk of Acute PancreatitisChina
-
Chinese Medical AssociationCompletedSevere Acute Pancreatitis | Pancreatic NecrosisChina
-
Jianbo YuNot yet recruitingSevere Acute Pancreatitis
-
First People's Hospital of ChenzhouUnknownSevere Acute PancreatitisChina
-
Sixth Hospital of Wuhan, Affiliated Hospital of...CompletedSevere Acute Pancreatitis PatientsChina
-
University Hospital, Clermont-FerrandCompleted